Table 3.
Odds ratio for nonrecovery of AKI according to SUA levels.
| SUA (mg/dl) | Unadjusted |
Model 1 |
Model 2 |
||||||
|---|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | p Value | OR | 95% CI | p Value | OR | 95% CI | p Value | |
| ≤3.6 | reference | reference | reference | ||||||
| >3.6–5.1 | 1.03 | 0.88–1.22 | 0.671 | 1.09 | 0.92–1.29 | 0.340 | 1.14 | 0.86–1.52 | 0.167 |
| >5.1–6.9 | 1.15 | 0.88–1.33 | 0.120 | 1.12 | 0.79–1.30 | 0.428 | 1.07 | 0.92–1.20 | 0.258 |
| >6.9 | 1.51 | 1.12–2.01 | 0.012 | 1.59 | 1.07–1.98 | <0.001 | 1.46 | 1.25–1.85 | <0.001 |
CI: confidence interval; OR: odds ratio; SUA: serum uric acid; AKI: acute kidney injury; CKD: chronic kidney disease; RRT: renal replacement therapy; eGFR: estimated glomerular filtration rate; BMI: body mass index.
Logistic regression: model 1 was adjusted for age, sex and BMI; model 2 was adjusted for age; sex; BMI; emergency status; AKI stage; presence of CKD, diabetes, hypertension, heart disease, or cancer; creatinine; albumin; cholesterol; triglyceride; Hb; eGFR and RRT requirement; and the use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta blockers, calcium channel blockers, furosemide and UA-lowering agents.
The mean variance inflation factor was 1.03 and 1.90 for Model 1 and Model 2, respectively.